No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration of ombitasvir/paritaprevir/ritonavir with emtricitabine/tenofovir-DF (200/300 mg once daily) decreased tenofovir Cmax by 20% and increased AUC and Cmin by 1% and 13%. Paritaprevir Cmax, AUC and Cmin increased by 2%, 4% and 9%. Changes in emtricitabine and ombitasvir PK parameters were similar to that observed with ombitasvir/paritaprevir/ritonavir + dasabuvir (emtricitabine: Cmax, AUC, Cmin increased by 5%, 7%, 9%, respectively; ombitasvir Cmax, AUC, Cmin decreased by 11%, 1%, 3%, respectively). Emtricitabine/tenofovir-DF can be administered with ombitasvir/paritaprevir/ritonavir and no dose alteration is required.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking